NF2 and meningioma: Conversely, in a clinical trial of meningioma patients with somatic loss of the neurofibromatosis type II (NF2) gene, FAK inhibitor monotherapy extended progression-free survival at six months in grade 1–3 tumors compared to historical controls (Brastianos et al., 2022).